Lung cancer has the highest morbidity and mortality among malignant tumors worldwidely. Targeted therapy related to non-small cell lung cancer (NSCLC) is the research hotspot in recent year. The emergence of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has brought a huge change in the treatment of patients with EGFR mutation. The patients with EGFR exon20 insertion are specific cohort in NSCLC. Reviewing the clinical researches to EGFR exon20 insertion mutation positive NSCLC, as well as summarizing character, testing methods and treatment, will provide a help for clinical application, bringing more benefits for patients at the same time.
【中文题目：EGFR基因20外显子插入突变在非小细胞肺癌的研究及其进展】 【中文摘要：全球肺癌发病率及死亡率居全部恶性肿瘤的首位，与非小细胞肺癌（non-small cell lung cancer, NSCLC）相关的治疗研究也是近年来的研究热点。表皮生长因子受体-酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosinekinase inhibitors, EGFR-TKIs）的出现，给携带EGFR基因突变的NSCLC患者治疗带来巨大的转变。但携带EGFR基因的20外显子插入突变（exon 20 insertion mutation, ex20ins mutation）患者却是EGFR基因突变群体中的特殊人群，往往对EGFR-TKIs耐药。本文对EGFR ex20ins突变相关的研究进行回顾分析，归纳其特点、检测手段、治疗手段，对EGFR ex20ins突变有更加全面的认识，将为临床应用提供帮助，为患者带来更大的益处。】 【中文关键词：表皮生长因子受体；20外显子；肺肿瘤；插入突变】.
Keywords: Epidermal growth factor receptor; Exon 20; Insertion mutation; Lung neoplasms.